Timelines.

Well we haven't done one of those @TonyIndo  style threads so let's put one together.

Link to Neuren's trials.

1. RETT - Fast Tracked. Orphan Drug Status.

- Rett Syndrome Update
- Scientific peer reviewed paper
- Pediatric Exclusivity
- More patents ?

* Successful Phase 2 trial with a pathway towards New Drug Application
* Orphan Drug designations granted by FDA and EMA
* Fast Track designation granted by the FDA

2. Fragile X ( NNZ-2566) Fast Tracked. Orphan Drug Status.

- Trial over - Succesful
- Additional Patents
- Pediatric Exclusivity.
- Peer reviewed paper.

* Successful Phase 2 trial with a pathway towards New Drug Application
* Orphan Drug designations granted by the FDA and the EMA
* Fast Track designation granted by the FDA

3. INTREPID Trial. Fast Tracked.

- Results in 2016 early.
- Peer reviewed paper
- Patents

* Fast Track designation granted by the FDA

4 Mild TBI

- Results in 2016 early.
- Peer reviewed paper
- Patents

Key strategic relationships

- US Army Medical Research & Materiel Command
- International Rett Syndrome Foundation (Rettsyndrome.org)
- FRAXA and National Fragile X Foundation

Cash ~ Approx 24 Million (Let the CR threads begin now)

Manufacturing

Hopefully we get to hear about who the 'number of parties' are that are refining the physical and technical attributes of NNZ-2566 as well as the optimisation of the manufacturing and projected unit costs re commercial supply of drug. The company stated that they have already identified significant opportunity in this area.


Partners